Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Soulagel
- Development stage
- Phase 3
- Lead developer
- Laboratoire Phytotech
- Administration
- Topical
01
Overview
Soulagel is a topical herbal gel developed for the management of acute musculoskeletal pain and soft tissue injuries. The formulation is composed of a synergistic blend of natural active ingredients, including menthol, camphor, and essential oils such as eucalyptus, rosemary, and lavender. It functions as a topical analgesic and anti-inflammatory agent, providing a cooling sensation and localized pain relief by targeting transient receptor potential (TRP) channels. Soulagel has been evaluated in clinical trials, notably by researchers at the Université de Monastir in Tunisia, as a potential alternative to topical non-steroidal anti-inflammatory drugs (NSAIDs) like piroxicam for patients presenting with acute extremity pain.
- Brand names
- Soulagel
Beyond the preview
Go deeper on Soulagel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Soulagel.